Taken together, these results illustrated that the administration of S1pr3 inhibitors in the early inflammatory phase of BLM-induced lung injury would ameliorate the formation of fibrosis by reducing the polarization of macrophage into M2 phenotype, suggesting that S1pr3-specific inhibitors represent a viable intervention approach against PF. Here, S1PR3 is linked to injury.